acetylcarnitine has been researched along with Inflammation in 13 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propionic acid (PPA) is a short-chain fatty acid produced endogenously by gut microbiota and found in foodstuffs and pharmaceutical products as an additive." | 5.72 | Acetyl-L-carnitine and/or liposomal co-enzyme Q10 prevent propionic acid-induced neurotoxicity by modulating oxidative tissue injury, inflammation, and ALDH1A1-RA-RARα signaling in rats. ( Abo-Hamad, A; Alhumaidan, S; Alhusaini, A; Almogren, R; Alsaif, S; Alsultan, E; Hasan, I; Hassanein, E; Mahmoud, A; Mattar, D; Sarawi, W, 2022) |
| " ALC (200mg/kg) lowered apomorphine-induced rotational asymmetry and reduced the latency to initiate and the total time in the narrow beam test, reduced striatal malondialdehyde (MDA), increased catalase activity and glutathione (GSH) level, prevented reduction of nigral tyrosine hydroxylase (TH)-positive neurons and striatal TH-immunoreactivity, and lowered striatal glial fibrillary acidic protein (GFAP) and its immunoreactivity as an indicator of astrogliosis, and nuclear factor NF-kappa B and Toll-like receptor 4 (TLR4) as reliable markers of neuroinflammation." | 3.85 | Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. ( Afshin-Majd, S; Baluchnejadmojarad, T; Bashiri, K; Kiasalari, Z; Roghani, M; Sedaghat, R, 2017) |
| "The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism." | 2.50 | Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014) |
| "Idiopathic oligoasthenoteratozoospermia (iOAT) affects approximately 30% of all infertile men." | 2.43 | Male idiopathic oligoasthenoteratozoospermia. ( Cavallini, G, 2006) |
| "Propionic acid (PPA) is a short-chain fatty acid produced endogenously by gut microbiota and found in foodstuffs and pharmaceutical products as an additive." | 1.72 | Acetyl-L-carnitine and/or liposomal co-enzyme Q10 prevent propionic acid-induced neurotoxicity by modulating oxidative tissue injury, inflammation, and ALDH1A1-RA-RARα signaling in rats. ( Abo-Hamad, A; Alhumaidan, S; Alhusaini, A; Almogren, R; Alsaif, S; Alsultan, E; Hasan, I; Hassanein, E; Mahmoud, A; Mattar, D; Sarawi, W, 2022) |
| "L-acetylcarnitine treatment enhanced mGlu2/3 receptor protein levels in the dorsal region of the spinal cord." | 1.46 | Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. ( Battaglia, G; Bernabucci, M; Bruno, V; Cannella, M; Gradini, R; Imbriglio, T; Mascio, G; Nicoletti, F; Notartomaso, S; Scarselli, P; Zappulla, C, 2017) |
| "Neuroinflammation is the inflammation of nervous tissue that can lead to neurodegeneration." | 1.46 | Neuroprotective effects of acetyl-l-carnitine on lipopolysaccharide-induced neuroinflammation in mice: Involvement of brain-derived neurotrophic factor. ( Kazak, F; Yarim, GF, 2017) |
| "Neuroinflammation was induced by lipopolysaccharide (LPS)." | 1.46 | Neuroprotective effects of acetyl-l-carnitine on lipopolysaccharide-induced neuroinflammation in mice: Involvement of brain-derived neurotrophic factor. ( Kazak, F; Yarim, GF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Alhusaini, A | 1 |
| Sarawi, W | 1 |
| Mattar, D | 1 |
| Abo-Hamad, A | 1 |
| Almogren, R | 1 |
| Alhumaidan, S | 1 |
| Alsultan, E | 1 |
| Alsaif, S | 1 |
| Hasan, I | 1 |
| Hassanein, E | 1 |
| Mahmoud, A | 1 |
| Bae, JE | 1 |
| Kim, JB | 1 |
| Jo, DS | 1 |
| Park, NY | 1 |
| Kim, YH | 1 |
| Lee, HJ | 1 |
| Kim, SH | 2 |
| Son, M | 1 |
| Kim, P | 1 |
| Ryu, HY | 1 |
| Lee, WH | 1 |
| Ryoo, ZY | 1 |
| Lee, HS | 1 |
| Jung, YK | 1 |
| Cho, DH | 1 |
| Ardizzone, A | 1 |
| Fusco, R | 1 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Impellizzeri, D | 1 |
| Esposito, E | 1 |
| Cuzzocrea, S | 1 |
| Notartomaso, S | 1 |
| Mascio, G | 1 |
| Bernabucci, M | 1 |
| Zappulla, C | 1 |
| Scarselli, P | 1 |
| Cannella, M | 1 |
| Imbriglio, T | 1 |
| Gradini, R | 1 |
| Battaglia, G | 1 |
| Bruno, V | 1 |
| Nicoletti, F | 1 |
| Mohammadi, M | 1 |
| Hajhossein Talasaz, A | 1 |
| Alidoosti, M | 1 |
| Kazak, F | 1 |
| Yarim, GF | 1 |
| Chen, DQ | 1 |
| Cao, G | 1 |
| Chen, H | 1 |
| Argyopoulos, CP | 1 |
| Yu, H | 1 |
| Su, W | 1 |
| Chen, L | 1 |
| Samuels, DC | 1 |
| Zhuang, S | 1 |
| Bayliss, GP | 1 |
| Zhao, S | 1 |
| Yu, XY | 1 |
| Vaziri, ND | 1 |
| Wang, M | 1 |
| Liu, D | 1 |
| Mao, JR | 1 |
| Ma, SX | 1 |
| Zhao, J | 1 |
| Zhang, Y | 1 |
| Shang, YQ | 1 |
| Kang, H | 1 |
| Ye, F | 1 |
| Cheng, XH | 1 |
| Li, XR | 1 |
| Zhang, L | 1 |
| Meng, MX | 1 |
| Guo, Y | 1 |
| Zhao, YY | 1 |
| Adamska-Patruno, E | 1 |
| Godzien, J | 1 |
| Ciborowski, M | 1 |
| Samczuk, P | 1 |
| Bauer, W | 1 |
| Siewko, K | 1 |
| Gorska, M | 1 |
| Barbas, C | 1 |
| Kretowski, A | 1 |
| Phillipson, OT | 1 |
| Afshin-Majd, S | 1 |
| Bashiri, K | 1 |
| Kiasalari, Z | 1 |
| Baluchnejadmojarad, T | 1 |
| Sedaghat, R | 1 |
| Roghani, M | 1 |
| Annadurai, T | 1 |
| Vigneshwari, S | 1 |
| Thirukumaran, R | 1 |
| Thomas, PA | 1 |
| Geraldine, P | 1 |
| Karalija, A | 1 |
| Novikova, LN | 1 |
| Kingham, PJ | 1 |
| Wiberg, M | 1 |
| Novikov, LN | 1 |
| Cavallini, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Analysis of Genetic Aspects of Metabolic Response on Diet With Different Content of Carbohydrate and Fat. Searching for Genetic Markers for Individualized Therapy in Patients With Obesity and Type 2 Diabetes[NCT03792685] | 150 participants (Actual) | Interventional | 2009-09-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for acetylcarnitine and Inflammation
| Article | Year |
|---|---|
Preventive effect of l-carnitine and its derivatives on endothelial dysfunction and platelet aggregation.
Topics: Acetylcarnitine; Animals; Antioxidants; Carnitine; Cell Adhesion; Cell Adhesion Molecules; Clinical | 2016 |
Management of the aging risk factor for Parkinson's disease.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb | 2014 |
Male idiopathic oligoasthenoteratozoospermia.
Topics: Acetylcarnitine; Animals; Antioxidants; Apoptosis; Autoimmunity; Chlamydia Infections; Chlamydia tra | 2006 |
10 other studies available for acetylcarnitine and Inflammation
| Article | Year |
|---|---|
Acetyl-L-carnitine and/or liposomal co-enzyme Q10 prevent propionic acid-induced neurotoxicity by modulating oxidative tissue injury, inflammation, and ALDH1A1-RA-RARα signaling in rats.
Topics: Acetylcarnitine; Animals; Antioxidants; Autism Spectrum Disorder; Inflammation; Neurotoxicity Syndro | 2022 |
Carnitine Protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Acetylcarnitine; Apoptosis; Carnitine; Cell Line, Tumor; Dopaminergic N | 2022 |
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain.
Topics: Acetylcarnitine; Amitriptyline; Analgesics; Animals; Chronic Disease; Disease Models, Animal; Epigen | 2017 |
Neuroprotective effects of acetyl-l-carnitine on lipopolysaccharide-induced neuroinflammation in mice: Involvement of brain-derived neurotrophic factor.
Topics: Acetylcarnitine; Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Inflamma | 2017 |
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |
The Type 2 Diabetes Susceptibility PROX1 Gene Variants Are Associated with Postprandial Plasma Metabolites Profile in Non-Diabetic Men.
Topics: Acetylcarnitine; Adult; Alleles; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet; Dietary Carb | 2019 |
Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Topics: Acetylcarnitine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine Agonists; Dopamin | 2017 |
Acetyl-L-carnitine prevents carbon tetrachloride-induced oxidative stress in various tissues of Wistar rats.
Topics: Acetylcarnitine; Alanine Transaminase; Alkaline Phosphatase; Animals; Antioxidants; Ascorbic Acid; A | 2011 |
Neuroprotective effects of N-acetyl-cysteine and acetyl-L-carnitine after spinal cord injury in adult rats.
Topics: Acetylcarnitine; Acetylcysteine; Animals; Antioxidants; Astrocytes; Female; Inflammation; Microglia; | 2012 |